EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Comparative Analysis of High-Dose Dual Therapies in First-Line Helicobacter pylori Eradication: An Inverse Probability of Treatment-Weighted Multicenter Study

Qingzhou Kong, Baobao Wang, Bengang Zhou iD, Hong Lu iD, Tianlian Yan, Yingying Han, Yanbing Ding, Peiyuan Li, Miao Duan, Kunping Ju, Wenrong Geng, Yuting Guo und 7 weitere

The Journal of Infectious Diseases · 15.05.2026 · 233 (5) · 966-974

DOI: 10.1093/infdis/jiag059 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 31.01.2026. Verfasst von Qingzhou Kong und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents, Proton Pump Inhibitors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High-dose dual therapy (HDDT) is a promising first-line treatment option for Helicobacter pylori infection. In this study, we aimed to compare the efficacy and safety of different HDDT regimens.

Methods

This multicenter retrospective study included data from 10 centers between January 2022 and January 2025. Inverse probability of treatment-weighted (IPTW) adjustment was used to address the imbalance in variables across groups. The outcomes included the eradication rate, adverse events, and adherence.

Results

A total of 1665 patients were included, with a full analysis set (FAS) eradication rate of 88.6% and a per-protocol (PP) eradication rate of 89.5% for HDDT. After IPTW adjustment, the eradication rate of vonoprazan–amoxicillin (VA) 14-day based on FAS analysis was 95.1%, which was significantly higher than VA-10 day (88.7%) (P = .001), esomeprazole–amoxicillin (EA) (85.1%) (P < .001), and tegoprazan–amoxicillin (TA) (87.3%) (P < .001). The incidence of adverse events for VA-14 was 8.1%, which was comparable to VA-10 (11.1%) but lower than TA (14.4%) and EA (15.3%) (P = .002). Adherence showed no significant difference across groups. High body surface area (BSA) (≥1.80 m²) (OR 1.594, 95% confidence interval [CI], 1.018–2.495, P = .041), poor adherence (OR 4.975, 95% CI, 2.753–8.992, P < .001), and non-VA-14 treatment regimen were independent risk factors for eradication failure. Factors varied across regimens.

Conclusions

HDDT, particularly VA-14, is a competitive first-line option for H. pylori eradication. High BSA and low adherence were risk factors for eradication failure but varied across regimens, highlighting the necessity of personalized adjustment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsHelicobacter pyloriAnti-Bacterial AgentsProton Pump InhibitorsHumansRetrospective StudiesDrug Therapy, CombinationAmoxicillinFemaleMaleMiddle AgedPyrrolesSulfonamidesTreatment OutcomeEsomeprazole

Stichwörter der Autor:innen

Helicobacter pyloriadherencebody surface areaeradication ratehigh-dose dual therapy

Substanzen

Anti-Bacterial AgentsAmoxicillinProton Pump InhibitorsPyrrolesSulfonamidesvonoprazanEsomeprazole

Autor:innen und Institutionen

  • Department of Gastroenterology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
  • Laboratory of Translational Gastroenterology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
  • Shandong Provincial Clinical Research Center for Digestive Disease, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Department of Gastroenterology, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, Jiangsu, China.
  • Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu, China.
  • Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, State Key Laboratory for Oncogenes and Related Genes, Renji Hospital, School of Medicine, Shanghai Jiao…

ORCID-Profile: Bengang Zhou, Hong Lu, Xiuli Zuo, Yueyue Li

Zitieren

APA

Kong, Q., Wang, B., Zhou, B., Lu, H., Yan, T., Han, Y., Ding, Y., Li, P., Duan, M., Ju, K., Geng, W., Guo, Y., Zhao, H., Song, X., Li, X., Long, X., Zuo, X., Li, Y., & Li, Y. (2026). Comparative Analysis of High-Dose Dual Therapies in First-Line Helicobacter pylori Eradication: An Inverse Probability of Treatment-Weighted Multicenter Study. The Journal of Infectious Diseases, 233(5), 966-974. https://doi.org/10.1093/infdis/jiag059

Vancouver

Kong Q, Wang B, Zhou B, Lu H, Yan T, Han Y, et al. Comparative Analysis of High-Dose Dual Therapies in First-Line Helicobacter pylori Eradication: An Inverse Probability of Treatment-Weighted Multicenter Study. The Journal of Infectious Diseases. 2026;233(5):966-974. doi:10.1093/infdis/jiag059

BibTeX
@article{Kong2026,
  author = {Kong, Qingzhou and Wang, Baobao and Zhou, Bengang and Lu, Hong and Yan, Tianlian and Han, Yingying and Ding, Yanbing and Li, Peiyuan and Duan, Miao and Ju, Kunping and Geng, Wenrong and Guo, Yuting and Zhao, Hongyu and Song, Xiaohui and Li, Xiaowei and Long, Xin and Zuo, Xiuli and Li, Yanqing and Li, Yueyue},
  title = {Comparative Analysis of High-Dose Dual Therapies in First-Line Helicobacter pylori Eradication: An Inverse Probability of Treatment-Weighted Multicenter Study},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  volume = {233},
  number = {5},
  pages = {966--974},
  doi = {10.1093/infdis/jiag059}
}
Kostenlos starten →